ALTTO test of dual HER2 blockade finds single agent remains the gold standard

(Mayo Clinic) In the largest clinical trial testing the effectiveness of one versus two drugs to treat HER2-positive breast cancer, lapatinib did not add benefit to the standard trastuzumab adjuvant therapy, researchers report at the 50th annual meeting of the American Society of Clinical Oncology.